In a nutshell This study compared surgery and radiotherapy for treating localized prostate cancer. They found no significant difference in survival between the two treatments. Some background Localized prostate cancer (cancer which has not spread beyond the prostate gland) can be treated with either surgery, radiotherapy, or monitoring without...
Read MoreProstate cancer Posts on Medivizor
Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?
In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...
Read MoreLooking for patients with high risk prostate cancer to trial a radiation treatment
In a nutshell This trial is aiming to investigate the effectiveness of stereotactic body radiotherapy (SBRT) boost for the treatment in patients with high-risk prostate cancer (PCa). The main outcome that will be measured will be the quality of life (QoL) of patients. This study is being carried out in Ontario, Canada. The details PCa is the...
Read MoreLatest ESMO guidelines for the treatment of prostate cancer
In a nutshell This review summarized clinical guidelines for treating prostate cancer (PC) recommended by the European Society for Medical Oncology (ESMO). The main recommendation was that all therapies should be risk-based and personalized. Some background Treatment recommendations for PC can vary across countries and time periods. It is important to...
Read MoreA comparison of high-dose vs. moderate-dose SBRT for prostate cancer.
In a nutshell This study was carried out to assess different dosing regimens of hypofractionated stereotactic body radiotherapy (SBRT) in patients with prostate cancer. The study found that both doses were associated with high effectiveness and manageable side effects. Some background Radiotherapy is an effective treatment for early-stage PC....
Read MoreSearching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination
In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...
Read MoreCan high-risk prostate cancer be treated with high-dose-rate brachytherapy, external beam radiotherapy plus long-term androgen deprivation therapy?
In a nutshell This study looked at whether the use of high-dose (HD) brachytherapy (BT) and hypofractionated external beam radiotherapy (EBRT) plus androgen-deprivation therapy (ADT) as a means of treatment for very high-risk prostate cancer (PCa). The study found that this treatment had significant benefits for patients with high-risk...
Read MoreIs there an association between statin use and the risk of prostate cancer mortality?
In a nutshell This study evaluated whether there was an association between statin (a type of cholesterol-lowering medication) use and prostate cancer (PCa) mortality. This study found that stain use resulted in lower rates of PCa-specific mortality, in particular with the use of hydrophilic statins. Some background PCa is one of the most common...
Read MoreCOVID-19 with Cancer
Recent research presented at a virtual meeting of the American Association for Cancer Research 1 indicates the need for greater care and continued social distancing for those who are in treatment for cancer and – in one study that was presented – those who have a recent history of cancer (the research looked at people from 2015 to the...
Read MoreComparing the effectiveness of apalutamide, darolutamide and enzalutamide in treating nonmetastatic castration-resistant prostate cancer
In a nutshell The study compared outcomes of apalutamide (A; Erleada), darolutamide (D; Nubeqa), and enzalutamide (E; Xtandi) in treating nonmetastatic castration-resistant prostate cancer (nmCRPC). The authors found that A and E had better metastasis-free survival (MFS) compared to D. Some background Men with CRPC fail to respond to...
Read MoreCan androgen deprivation therapy combined with docetaxel plus prednisone improved outcomes in patients with metastatic hormone-sensitive prostate cancer?
In a nutshell The aim of this study was to evaluate the safety and effectiveness of combining androgen deprivation therapy (ADT) with docetaxel (Taxotere) plus prednisone (Deltasone) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The study found that this combination improved the outcomes of these...
Read MoreThe effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer
In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...
Read More